TY - JOUR
T1 - S100B and Inflammatory Cytokine Levels in Blood as Potential Markers of Blood–Brain Barrier Damage and Psychiatric Impairment in Comorbid Hepatitis C Viral Infection and Alcohol Use Disorder
AU - Loftis, Jennifer M.
AU - Valerio, Juno
AU - Taylor, Jonathan
AU - Huang, Elaine
AU - Hudson, Rebekah
AU - Taylor-Young, Patricia
AU - Chang, Michael
AU - Ho, Samuel B.
AU - Dieperink, Eric
AU - Miranda, Juan Luis
AU - Hauser, Peter
N1 - Funding Information:
The authors would like to thank the study participants, staff at the recruitment sites (particularly, Ms. Alissa Phelps for study coordination), and the VA Pathology and Laboratory Services.
Funding Information:
This work was supported by the U.S. Department of Veterans Affairs Biomedical Laboratory Research and Development Merit Review grant # I01 BX002061 (JML) and Clinical Sciences Research and Development Merit Review project # NURA-014-09S (PH) [ClinicalTrials.gov Info: # NCT01008280 Baclofen to Reduce Alcohol Use in Veterans With HCV (BRAC) https://clinicaltrials.gov/ct2/ show/NCT01008280?term=NCT01008280&rank=1]. The work was also supported by the National Institute on Drug Abuse grant #: DA P50DA018165 (JML). The work was conducted using facilities at Veterans Affairs Health Care Systems (Portland, OR; Long Beach, CA; San Diego, CA; and Minneapolis, MN) and Oregon Health & Science University, Portland, OR. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.
Publisher Copyright:
Published 2018. This article is a U.S. Government work and is in the public domain in the USA
PY - 2018/8
Y1 - 2018/8
N2 - Background: Hepatitis C virus (HCV) infection and alcohol use disorder (AUD) both adversely affect the immune system resulting in alterations in immune cell signaling and inflammatory processes. The aim of this study was to investigate how comorbid AUD contributes to abnormalities in inflammatory mediators and psychiatric impairments in adults with HCV. Methods: Alcohol use, mood, and inflammatory factors were evaluated at 3 time points (baseline, week 4, and week 12) in Veterans with HCV, with (n = 42) and without (n = 13) comorbid AUD. Peripheral indices of immune activation, blood–brain barrier (BBB) damage (S100 calcium-binding protein B [S100B]), liver function, and viral load were measured using immunoassays and polymerase chain reaction assays. Results: Comorbid AUD was associated with increased symptoms of depression and anxiety, elevated levels of liver enzymes, and altered expression of inflammatory factors. Alcohol consumption was positively correlated with the severity of psychiatric symptoms. Univariate analysis identified significant group differences in interleukin (IL)-8 (p = 0.006), IL-10 (p = 0.03), and S100B (p = 0.048), with increased levels in participants with AUD, which persisted over time despite reductions in alcohol use and no significant change in HCV viral load. Statistically significant effects of study group or time were not found for the other immune factors assessed. Exploratory receiver operating characteristic curve analysis evaluated the ability of IL-8, IL-10, and S100B to differentiate between levels of alcohol consumption and generated biomarker cutoff values used to identify low risk and unhealthy alcohol use groups. Conclusions: These results demonstrate that HCV and comorbid AUD are associated with greater psychiatric impairments, potentially resulting from increased inflammation, dysregulated cytokine expression, and compromised BBB function. Alcohol-induced BBB damage may increase the risk of neuropathological consequences within the context of chronic HCV infection.
AB - Background: Hepatitis C virus (HCV) infection and alcohol use disorder (AUD) both adversely affect the immune system resulting in alterations in immune cell signaling and inflammatory processes. The aim of this study was to investigate how comorbid AUD contributes to abnormalities in inflammatory mediators and psychiatric impairments in adults with HCV. Methods: Alcohol use, mood, and inflammatory factors were evaluated at 3 time points (baseline, week 4, and week 12) in Veterans with HCV, with (n = 42) and without (n = 13) comorbid AUD. Peripheral indices of immune activation, blood–brain barrier (BBB) damage (S100 calcium-binding protein B [S100B]), liver function, and viral load were measured using immunoassays and polymerase chain reaction assays. Results: Comorbid AUD was associated with increased symptoms of depression and anxiety, elevated levels of liver enzymes, and altered expression of inflammatory factors. Alcohol consumption was positively correlated with the severity of psychiatric symptoms. Univariate analysis identified significant group differences in interleukin (IL)-8 (p = 0.006), IL-10 (p = 0.03), and S100B (p = 0.048), with increased levels in participants with AUD, which persisted over time despite reductions in alcohol use and no significant change in HCV viral load. Statistically significant effects of study group or time were not found for the other immune factors assessed. Exploratory receiver operating characteristic curve analysis evaluated the ability of IL-8, IL-10, and S100B to differentiate between levels of alcohol consumption and generated biomarker cutoff values used to identify low risk and unhealthy alcohol use groups. Conclusions: These results demonstrate that HCV and comorbid AUD are associated with greater psychiatric impairments, potentially resulting from increased inflammation, dysregulated cytokine expression, and compromised BBB function. Alcohol-induced BBB damage may increase the risk of neuropathological consequences within the context of chronic HCV infection.
KW - Alcohol Use Disorders
KW - Blood–Brain Barrier
KW - Cytokines
KW - Depression
KW - Hepatitis C
UR - http://www.scopus.com/inward/record.url?scp=85051066056&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051066056&partnerID=8YFLogxK
U2 - 10.1111/acer.13796
DO - 10.1111/acer.13796
M3 - Article
AN - SCOPUS:85051066056
SN - 0145-6008
VL - 42
SP - 1466
EP - 1475
JO - Alcoholism: Clinical and Experimental Research
JF - Alcoholism: Clinical and Experimental Research
IS - 8
ER -